Adverse events · heavy menstrual bleeding
LNG‐IUS probably leads to lower adverse events compared with any other medical treatment (moderate certainty).
1 finding from 1 review
Treatment withdrawal for any reason Duration of treatment (range): 12 (3 months) to 36 weeks · heavy menstrual bleeding
LNG‐IUS probably leads to lower withdrawal from treatment for any reason compared with any other medical treatment (moderate certainty).
1 finding from 1 review
Treatment failure · heavy menstrual bleeding
LNG‐IUS probably leads to lower treatment failure compared with any other medical treatment (moderate certainty).
1 finding from 1 review
Costs · heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bleeding · heavy menstrual bleeding
1 finding from 1 review
Satisfaction with treatment · heavy menstrual bleeding
LNG‐IUS showed no clear difference in satisfaction with treatment compared with endometrial ablation (low certainty).
1 finding from 1 review
Regression of EH; by length of · endometrial hyperplasia
LNG‐IUS probably leads to higher regression of EH; by length of compared with non‐intrauterine progestogen (moderate certainty).
2 findings from 1 review
Hysterectomy; histologically and non‐histologically indicated · endometrial hyperplasia
LNG‐IUS may leads to lower hysterectomy; histologically and non‐histologically indicated compared with non‐intrauterine progestogen (low certainty).
1 finding from 1 review
Adverse effects associated with hormones:Bleeding/spotting Nausea Weight gain · endometrial hyperplasia
It is very uncertain whether LNG‐IUS changes adverse effects associated with hormones:Bleeding/spotting Nausea… compared with non‐intrauterine progestogen (very low certainty).
1 finding from 1 review
Adverse effects requiring withdrawal/discontinuation of study medication · endometrial hyperplasia
LNG‐IUS showed no clear difference in withdrawal secondary to adverse effects compared with non‐intrauterine progestogen (low certainty).
1 finding from 1 review
Satisfaction with treatment · endometrial hyperplasia
It is very uncertain whether LNG‐IUS changes satisfaction with treatment compared with non‐intrauterine progestogen (very low certainty).
1 finding from 1 review
Overall pain at 12 months  · Patients with symptomatic endometriosis following surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Chronic pelvic pain at 12 months Â
1 finding from 1 review
Dysmenorrhoea at 12 months Â
1 finding from 1 review
Improvement of the most troublesome symptom at 12 months Â
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at 12 months Â
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction at 12 monthsÂ
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Â
1 finding from 1 review
Chronic pelvic pain at 12 months  · Patients with symptomatic endometriosis following surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dysmenorrhoea at 12 months  · Patients with symptomatic endometriosis following surgery
1 finding from 1 review
no estimate extracted
95 participants
Very low